%20(1).jpg/r%5Bwidth%5D=1280&r%5Bheight%5D=720/85d570c0-120c-11ef-bfe1-7f53b05b4353-Morton_Jeff_1100x1100%20(1)%20(1).webp)
14 October 2026 Growing demand from life sciences and healthcare clients prompts an expansion in California, bringing the firm closer to biotechnology companies, research institutions and key courts for its Southern California litigators.
14 October 2026
13 October 2026
13 October 2026
12 October 2026
More News
8 October 2026 Following ANDA litigation over Tafinlar earlier this year, the Swiss multinational has sued the generics maker over its proposed version of Mekinist, asserting patents that cover both the composition and treatment regimen.
8 October 2026 Rival Halozyme secures a major patent victory against the pharma giant, blocking the subcutaneous version of its blockbuster cancer drug Keytruda across eight countries as MSD faces mounting pressure ahead of key patent expirations.
8 October 2026 The firm has snapped up IP partners from Sheridan Ross as it ramps up its presence in Denver and targets growing demand from life sciences and technology clients.
7 October 2026 With resources under pressure, the Danish company’s IP leader explains how AI, smarter prioritisation and close business ties can help IP teams boost their impact.
6 October 2026 Day one of the UK patent trial over blockbuster drug Jardiance put a lack of biological data, disputed evidence of testing and the limits of scientific prediction under the spotlight.
6 October 2026 The new partner advises technology and life sciences companies in Section 337 investigations and related patent disputes, drawing on extensive private practice and government experience.
5 October 2026 Tapio Blanc, chief trademark officer at Roche, explains why fighting fakes can be a matter of life and death, and how AI, online platforms, and ‘mousetrap buys’ are affecting brand protection.
Latest Features
Pharma
A medicine reaching the end of its primary patent term does not necessarily mean the market is open to generics. The complex patent landscape surrounding semaglutide shows how secondary patents covering indications, formulations and manufacturing processes can extend competitive barriers—and why careful freedom-to-operate analysis is critical before launch, says Ana Neves of Inventa.
Pharma
Reflecting on decades of patent searching experience, senior scientist on the CAS IP Services team, David Saari, offers insights into the importance of a multidisciplinary approach in today's competitive IP landscape.
MedTech
A new UPC Court of Appeal ruling closes an important procedural gap, with significant implications for how in-house teams structure validity defences, manage litigation costs and prepare for appeals, says Florian Laus of Simmons & Simmons.
Pharma
Canada has firmly slammed the door on patenting methods of medical treatment—but the battle over what counts as a "medical method" is only just beginning. Scott MacKendrick of ROBIC examines a landmark decision that leaves the door ajar for future litigation over complex drug-dosing regimens.
Europe
Europe’s latest patent fee increases are modest at the EPO but include a rare steep hike in the UK, forcing applicants to reassess filing routes, portfolio value, and long-term cost strategies, say James Bell and Yelena Morozova.
Asia
The clash between one of India’s largest B2B marketplaces and the country’s drugs regulator challenges the “passive” position of such platforms with regards to allegedly unlawful pharmaceutical listings, says Aarti Aggarwal of Remfry & Sagar.
Europe
After an overwhelmingly positive Supreme Court ruling for companies working in AI, Rachel Free of CMS outlines the necessary practical steps for patent holders—including enforcement of the ‘black box’ tech, the ruling’s influence on the UPC, and how to manage related applications.
Americas
From public use and foreign sales to the challenges of proving infringement, plant patents present unique legal opportunities—and pitfalls—for the agricultural industry, explain Bree Vculek, Gaby Longsworth, and Robert Millonig of Sterne Kessler.
Latest Events Videos
Americas
Integrating AI into patent workflows promises efficiency gains, but requires strict oversight regarding accuracy, ethics, and data security. This panel explores the practical realities of deploying AI tools responsibly while maintaining the high standards required in life sciences prosecution.
Americas
Is Brazil moving toward a more predictable patent system, or simply shifting risk? This session examines the far-reaching impact of the ADI 5529 ruling, analysing how the end of automatic patent term extensions is reshaping filing and enforcement strategies.
Regulation & Industry
The post-grant challenge landscape is intensifying on both sides of the Atlantic. This panel analyses recent developments in IPRs, PGRs, EPO oppositions, and the UPC, detailing strategies to simultaneously defend existing portfolios and clear competitive space.
Americas
Choosing between patent protection and trade secrets is a delicate balancing act, especially amid regulatory scrutiny and unpredictable patent office timelines. This session delves into the frontlines of IP strategy, offering practical guidance on when each protection mechanism serves best.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox